Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 12/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL789857 | 0.88 | ABCB11 (0.36) | DHODHCMKLR1 | |
| SCHEMBL9494124 | 0.79 | DHODH (0.42) | DHODHPARP1 | |
| SCHEMBL9491706 | 0.75 | DHODH (0.42) | DHODHPARP1CMKLR1 | |
| SCHEMBL9491813 | 0.74 | DHODH (0.40) | DHODHCMKLR1 | |
| SCHEMBL9492313 | 0.73 | CMKLR1 (0.34) | DHODHCMKLR1 | |
| SCHEMBL844427 | 0.72 | ABCB11 (0.38) | — | |
| SCHEMBL9638155 | 0.72 | DHODH (0.43) | DHODHPARP1CMKLR1 | |
| SCHEMBL2512493 | 0.71 | AGTR2 (0.51) | — | |
| SCHEMBL8944173 | 0.70 | KDM4E (0.40) | DHODH | |
| SCHEMBL9491579 | 0.70 | PARP1 (0.44) | DHODHPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546145-B2 | Combination therapy for the treatment of chronic renal failure with an angiotensin II receptor antagonist and beraprost | TORAY INDUSTRIES, INC. (JP) | 2017-01-17 | — | — | US | disclosed |
| US-20090176848-A1 | FORTIFIER | TORAY INDUSTRIES, INC., A CORPORATION OF JAPAN (JP) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176848-A1 | FORTIFIER | REN, ACE, PTGER1 | DHODH 1773/4885PARP1 2264/4885CMKLR1 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.